{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:10:15Z","timestamp":1726762215762},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,2,15]]},"DOI":"10.2169\/internalmedicine.6010-20","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T22:26:59Z","timestamp":1609194419000},"page":"639-643","source":"Crossref","is-referenced-by-count":5,"title":["Immediate Amelioration of Severe Respiratory Distress in Sj\u00f6gren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab"],"prefix":"10.2169","volume":"60","author":[{"given":"Hiroshi","family":"Kataoka","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sapporo City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sapporo City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. World Health Organization. Clinical management of COVID-19: interim guidance. 2020."},{"key":"2","unstructured":"2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Forthcoming."},{"key":"3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062, 2020.","journal-title":"The Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79: 667-668, 2020.","DOI":"10.1136\/annrheumdis-2020-217424"},{"key":"5","unstructured":"5. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. Forthcoming."},{"key":"6","unstructured":"6. Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. Forthcoming."},{"key":"7","unstructured":"7. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. Forthcoming."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sj\u00f6gren's syndrome. Eur Respir Rev 25: 110-123, 2016.","DOI":"10.1183\/16000617.0011-2016"},{"key":"9","unstructured":"9. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging 101: 263-268, 2020."},{"key":"#cr-split#-10.1","unstructured":"10. Treatment guideline for COVID-19. 4th ed. The Japanese Association for Infectious Diseases [Internet]. [updated 2002 May 28"},{"key":"#cr-split#-10.2","unstructured":"cited 2020 Jul 10]. Available from: https:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid19_drug_200605.pd (in Japanese)."},{"key":"11","unstructured":"11. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. Forthcoming."},{"key":"12","unstructured":"12. Song J, Li Y, Huang X, et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J Med Virol. Forthcoming."},{"key":"13","unstructured":"13. Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. Forthcoming."},{"key":"14","unstructured":"14. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A Review. JAMA. Forthcoming."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130: 2620-2629, 2020.","DOI":"10.1172\/JCI137244"},{"key":"16","unstructured":"16. Woodcock T, Barker P, Daniel S, et al. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK. Anaesthesia 75: 654-663, 2020."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 52: 731-733, 2020.","DOI":"10.1016\/j.immuni.2020.04.003"},{"key":"18","unstructured":"18. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. Forthcoming."},{"key":"19","unstructured":"19. Goto H, Makita S, Kato K, et al. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed\/refractory diffuse large B-cell lymphoma. Int J Clin Oncol. Forthcoming."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7: 303ra139, 2015.","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24: 739-748, 2018.","DOI":"10.1038\/s41591-018-0036-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology 2020.","DOI":"10.1016\/S2665-9913(20)30173-9"},{"key":"23","unstructured":"23. Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest. Forthcoming."},{"key":"24","unstructured":"24. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. Forthcoming."},{"key":"25","unstructured":"25. Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care 20: 329, 2016."},{"key":"26","unstructured":"26. Tasaka S, Tatsumi K. Assembly of Pulmonary Circulation, Lung Injury tJRS clinical practice of acute respiratory distress syndrome in Japan: a nationwide survey and scientific evidences. Respir Investig 55: 257-263, 2017."},{"key":"27","unstructured":"27. Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne) 7: 170, 2020."},{"key":"28","unstructured":"28. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 76: 43-49, 2020."},{"key":"29","unstructured":"29. Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 19: 102568, 2020."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Antinori S, Bonazzetti C, Gubertini G, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun Rev 19: 102564, 2020.","DOI":"10.1016\/j.autrev.2020.102564"},{"key":"31","unstructured":"31. Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. Forthcoming."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/4\/60_6010-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T19:05:38Z","timestamp":1670612738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/4\/60_6010-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6010-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}